• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Oncocyte Corporation (Amendment)

    4/15/24 7:26:25 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $OCX alert in real time by email
    SC 13D/A 1 d11029026_13d-a.htm

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

     

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 11)

     

     

    Oncocyte Corporation
    (Name of Issuer)

     

     

    Common Stock, no par value
    (Title of Class of Securities)

     

     

    68235C206
    (CUSIP Number)

     

     

    Neal C. Bradsher

    c/o Broadwood Capital, Inc.

    142 West 57th Street, 11th Floor

    New York, New York 10019

    (212) 508-5735

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

     

    April 11, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [_].
     

     

     

      

     

     

    CUSIP No. 68235C206    
         

     

    1. NAME OF REPORTING PERSONS  
         
      Broadwood Partners, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [X]
         
    3. SEC USE ONLY  
         
         
         
    4. SOURCE OF FUNDS  
         
      WC  
         
    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
         
    7. SOLE VOTING POWER  
         
      0  
         
    8. SHARED VOTING POWER  
         
      5,079,159  
         
    9. SOLE DISPOSITIVE POWER
         
      0  
         
    10. SHARED DISPOSITIVE POWER   [_]
         
      5,079,159  
     

     

     

     

     
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
         
      5,079,159  
         
    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES  
         
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      37.6%  
         
    14. TYPE OF REPORTING PERSON  
         
      PN  
         
         
         

     

     
     

     

    CUSIP No. 68235C206    
         

     

    1. NAME OF REPORTING PERSONS  
         
      Broadwood Capital, Inc.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [X]
         
    3. SEC USE ONLY  
         
         
         
    4. SOURCE OF FUNDS  
         
      AF  
         
    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      New York  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
         
    7. SOLE VOTING POWER  
         
      0  
         
    8. SHARED VOTING POWER  
         
      5,079,159  
         
    9. SOLE DISPOSITIVE POWER
         
      0  
         
    10. SHARED DISPOSITIVE POWER   [_]
         
      5,079,159  

     

     

     

       
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
         
      5,079,159  
         
    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES  
         
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      37.6%  
         
    14. TYPE OF REPORTING PERSON  
         
      CO, IA  
         

     

     
     

     

    CUSIP No. 68235C206    
         

     

    1. NAME OF REPORTING PERSONS  
         
      Neal C. Bradsher  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
        (a)   [_]
        (b)   [X]
         
    3. SEC USE ONLY  
         
         
         
    4. SOURCE OF FUNDS  
         
      PF, AF  
         
    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]
         
         
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
         
    7. SOLE VOTING POWER  
         
      157  
         
    8. SHARED VOTING POWER  
         
      5,079,159  
         
    9. SOLE DISPOSITIVE POWER
         
      157  
         
    10. SHARED DISPOSITIVE POWER   [_]
         
      5,079,159  

     

     

     

       
    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
      PERSON  
         
      5,079,316  
         
    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
      CERTAIN SHARES  
         
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      37.6%  
         
    14. TYPE OF REPORTING PERSON  
         
      IN, HC  
         

     

     
     

     

    CUSIP No. 68235C206    
         
    Item 1. Security and Issuer.  
         
     

    The name of the issuer is Oncocyte Corporation, a California corporation (the “Issuer”). The address of the Issuer’s principal executive office is 15 Cushing, Irvine, California 92618. This Amendment No. 11 to Schedule 13D relates to the Issuer’s Common Stock, no par value (the “Shares”).

     

     
         

     

    Item 2. Identity and Background.  
         
      (a), (f) The persons filing this statement are: (i) Broadwood Partners, L.P., a Delaware limited partnership (“Broadwood Partners”); (ii) Broadwood Capital, Inc., a New York corporation (“Broadwood Capital”); and (iii) Neal C. Bradsher, a United States citizen (“Mr. Bradsher”, and collectively with Broadwood Partners and Broadwood Capital, the “Reporting Persons”).  
           
      (b), (c) Broadwood Capital is an investment adviser registered with the Securities and Exchange Commission (the “SEC”) that is principally engaged in the business of providing investment advisory services.  Broadwood Partners is a pooled investment vehicle that is principally engaged in the business of investing its assets in securities.  Broadwood Capital serves as the general partner of Broadwood Partners.  Neal Bradsher is the President of Broadwood Capital.  The principal business address of the Reporting Persons is: c/o Broadwood Capital, Inc., 142 West 57th Street, 11th Floor, New York, New York 10019.    
           
      (d) None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).  
           
      (e)

    None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     
           
     
     

     

     

    Item 3.

     

    Source and Amount of Funds or Other Consideration.

     
           
     

    The funds for the purchase of the 5,079,159 Shares beneficially owned by Broadwood Partners came from its working capital. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

     

    The funds for the purchase of the 5,079,159 Shares beneficially owned by Broadwood Capital came from the working capital of Broadwood Partners, which is the direct owner of the Shares. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

     

    The funds for the purchase of the 5,079,316 Shares beneficially owned by Mr. Bradsher came from his personal funds and the working capital of Broadwood Partners. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

     

     
           

     

     
     

     

    Item 4. Purpose of Transaction.  
         
     

    The Reporting Persons acquired their Shares for investment and are filing this Schedule 13D/A to report that, on April 11, 2024, Broadwood Partners entered into a Securities Purchase Agreement with the Issuer (the “Securities Purchase Agreement”) pursuant to which Broadwood Partners agreed to acquire 2,420,000 Shares from the Issuer in a private placement (the “Private Placement”) for a total purchase price of $7,057,688, or $2.9164 per Share. In connection with Private Placement, the Issuer and Broadwood Partners also entered into a Registration Rights Agreement on April 11, 2024 pursuant to which the Issuer agreed to file a registration statement for purposes of registering the resale of the Shares acquired by Broadwood Partners pursuant to the Securities Purchase Agreement.

     

    The foregoing was a summary of certain material terms of the: (i) Securities Purchase Agreement; and (ii) Registration Rights Agreement. However, such summary is not, and does not purport to be, complete and is qualified in its entirety by reference to the full text of the: (i) Form of the Securities Purchase Agreement; and (ii) Form of Registration Rights Agreement, which have been filed as Exhibits B and C, respectively, and are incorporated herein by reference.

     

    In addition, on April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the “Series A Shares”) previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the “Series A Purchase Agreement”). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer’s mandatory redemption.

     

    Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own in open-market or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable.

     

     
     

    The Reporting Persons have been, and may continue to be, in contact with members of the Issuer’s management, the board of directors of the Issuer (the “Board of Directors”), other significant shareholders and others regarding alternatives that the Issuer could employ to maximize the creation of shareholder value over time.

     

    The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should they determine to do so, and/or to recommend courses of action to shareholders, the Board of Directors and/or the management of the Issuer.

     
           

     

     

    Item 5. Interest in Securities of the Issuer.  
         
      (a) – (d) As of the date hereof, Broadwood Partners may be deemed to be the beneficial owner of 5,079,159 Shares, constituting 37.6% of the Shares, based upon 13,500,066 Shares outstanding as of the date hereof, as adjusted to include warrants of the Issuer beneficially owned by Broadwood Partners.  Broadwood Partners has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 5,079,159 Shares.  Broadwood Partners has sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition 5,079,159 Shares.  
           
        As of the date hereof, Broadwood Capital may be deemed to be the beneficial owner of 5,079,159 Shares, constituting 37.6% of the Shares, based upon 13,500,066 Shares outstanding as of the date hereof, as adjusted to include warrants of the Issuer beneficially owned by Broadwood Capital.  Broadwood Capital has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 5,079,159 Shares.  Broadwood Capital has sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition 5,079,159 Shares.  
           
       

    As of the date hereof, Mr. Bradsher may be deemed to be the beneficial owner of 5,079,316 Shares, constituting 37.6% of the Shares, based upon 13,500,066 Shares outstanding as of the date hereof, as adjusted to include warrants of the Issuer beneficially owned by Mr. Bradsher. Mr. Bradsher has the sole power to vote or direct the vote of 157 Shares and the shared power to vote or direct the vote of 5,079,159 Shares. Mr. Bradsher has sole power to dispose or direct the disposition of 157 Shares and the shared power to dispose or direct the disposition 5,079,159 Shares.

     

    Other than (i) the Shares acquired by Broadwood Partners pursuant to the Securities Purchase Agreement, and (ii) the Issuer’s mandatory redemption of all of Broadwood Partner’s Series A Shares, in each case as described in Item 4 above, there have been no transactions in the Shares by the Reporting Persons during the past sixty days.

     

     

     
      (e)

    N/A

     

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect  
      to Securities of the Issuer.  
     

     

    The information set forth in Item 4 above is incorporated by reference in its entirety in this Item 6. The Reporting Persons do not have any contract, arrangement, understanding or relationship with any person with respect to securities of the Issuer that is not described herein and/or in a previous Schedule 13D filed by the Reporting Persons in respect of the Issuer.

     

     
         

     

    Item 7. Material to be Filed as Exhibits.  
         
     

    Exhibit A: Joint Filing Agreement

     

    Exhibit B: Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC by the Issuer on April 12, 2024)

     

    Exhibit C: Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC by the Issuer on April 12, 2024)

     

     
         
     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated:  April 15, 2024

    Broadwood Partners, L.P.*

     

      By: Broadwood Capital, Inc.
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
         
     

     

     

     
      Broadwood Capital, Inc.*
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
     

     

     

     
       
      /s/ Neal C. Bradsher
      Neal C. Bradsher*
       

     

     

    * This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

     

    JOINT FILING AGREEMENT

     

    The undersigned agree that this Amendment No. 11 to Schedule 13D, dated April 15, 2024, relating to the Common Stock, no par value, of Oncocyte Corporation shall be filed on behalf of the undersigned.

     

     

     

    Dated:  April 15, 2024

    Broadwood Partners, L.P.

     

      By: Broadwood Capital, Inc.
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
         
         
      Broadwood Capital, Inc.
       
      By: /s/ Neal C. Bradsher
      Name: Neal C. Bradsher
      Title: President
       

     

     

         
      /s/ Neal C. Bradsher
      Neal C. Bradsher

     

    Get the next $OCX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCX

    DatePrice TargetRatingAnalyst
    3/28/2025$5.00Buy
    Lake Street
    5/24/2022Overweight → Equal-Weight
    Stephens
    3/14/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    3/11/2022$11.00 → $6.00Buy
    Lake Street
    3/11/2022$5.00 → $4.00Buy
    Needham
    1/7/2022$3.10Overweight
    Stephens & Co.
    1/6/2022$3.10Overweight
    Piper Sandler
    12/16/2021$7.00 → $5.00Buy
    Needham
    More analyst ratings

    $OCX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation

      SCHEDULE 13G/A - Oncocyte Corp (0001642380) (Subject)

      5/9/25 4:06:55 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Oncocyte Corp (0001642380) (Filer)

      4/17/25 5:17:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 424B3 filed by Oncocyte Corporation

      424B3 - Oncocyte Corp (0001642380) (Filer)

      4/8/25 6:10:29 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

      Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay. The publication, "Association of Blood Donor-derived Cell-free DNA Levels with Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational Study," is c

      4/29/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Leadership Updates

    Live Leadership Updates

    See more

    $OCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $OCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

      Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and clinical goals for Oncocyte. Dr. Billings is a recognized pioneer in genomics and precision medicine with over 40 years of experience spanning academia, government,

      1/8/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

      NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (NASDAQ:OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, Oncocyte is poised for a transformative period with its upcoming commercial launches. The company's flagship products, the VitaGraft™ Kidney diagnostic test and its research use only (RUO) GraftAssure

      6/24/24 12:41:19 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      12/9/24 5:30:06 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      11/14/24 1:26:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      10/24/24 12:13:28 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Financial Officer James Andrea S.

      4 - Oncocyte Corp (0001642380) (Issuer)

      3/28/25 4:05:18 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by VP ACCT, Cntlr, Treasurer, PAO Liu James Yang

      4 - Oncocyte Corp (0001642380) (Issuer)

      3/28/25 4:05:17 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by CEO and President Riggs Josh

      4 - Oncocyte Corp (0001642380) (Issuer)

      3/28/25 4:05:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OncoCyte with a new price target

      Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

      3/28/25 8:35:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by Stephens

      Stephens downgraded OncoCyte from Overweight to Equal-Weight

      5/24/22 8:51:33 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded OncoCyte from Overweight to Sector Weight

      3/14/22 7:21:22 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Financials

    Live finance-specific insights

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance